<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00396409</url>
  </required_header>
  <id_info>
    <org_study_id>CIGE025ADE03</org_study_id>
    <nct_id>NCT00396409</nct_id>
  </id_info>
  <brief_title>Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis</brief_title>
  <official_title>A Randomized, 20 Week, Double-blind, Placebo-controlled, Parallel-group, Multiple-dose, Multicenter Study to Assess the Efficacy and Safety of Omalizumab in Combination With Depigoid, Versus Depigoid Only, in Adult and Adolescent Patients With Seasonal Allergic Asthma and Comorbid Seasonal Allergic Rhinoconjunctivitis - Open-label Depigoid Monotherapy Extension Periods 2007 and 2008-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Efficacy/ safety for the combination of anti-IgE (Omalizumab) and specific immunotherapy
      (Depigoid) in patients with not adequately controlled seasonal allergic asthma and comorbid
      seasonal allergic rhinoconjunctivitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label extension period of the previously randomized, multicenter,
      double-blind, placebo-controlled, parallel-group trial to demonstrate the benefit of pre- and
      co-seasonal combination therapy with anti-IgE (omalizumab) and specific immunotherapy
      (Depigoid) in patients with seasonal allergic asthma and co-morbid seasonal allergic
      rhinoconjunctivitis. During the open-label period, all patients received Depigoid monotherapy
      for two follow-up seasons every 4 weeks, 26 injections in total. The extension period was
      performed to evaluate the influence of omalizumab on the follow-up treatment with Depigoid in
      seasonal asthma.

      This study was a follow-up to the core IGE025ADE03 study, in which patients received
      omalizumab treatment. In this follow-up study, no patient received omalizumab.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily Symptom Load</measure>
    <time_frame>Recorded daily during the 2007 and 2008 pollen season</time_frame>
    <description>The daily symptom load (low=0, high=unbounded) represents the daily combined asthma and rhinoconjunctivitis symptom severity scores plus the daily asthma rescue medication score based on patient diary entries. A higher score indicates a worse patient asthma condition. Symptoms (e.g. - difficulty breathing, cough, tightness of chest, sneezing, itchy nose, red eyes, etc.) were evaluated daily by the patient using a 4-point scale (0=no symptom, 1=mild, 2=moderate, 3=severe). Point values were assigned by specific rescue medication usage. The daily scores were averaged over pollen days by site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma/Rhinoconjunctivitis Symptom Severity Score</measure>
    <time_frame>Recorded daily during the 2007 and 2008 pollen season</time_frame>
    <description>The symptom severity score was defined as the mean of the daily symptom severity scores (asthma symptoms during the day, asthma symptoms at night, rhinitis symptoms, and conjunctivitis symptoms) during the pollen season. The daily symptom severity scores were evaluated daily by the patient using a 4-point scale (0 = none (no symptom), 1 = mild, 2 = moderate, 3 = severe) and were recorded in a patient diary. The possible minimum value for the Asthma/Rhinoconjunctivitis Symptom Severity Score is 0, and the possible maximum value is 3. Higher values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma/Rhinoconjunctivitis Rescue Medication Score</measure>
    <time_frame>Recorded daily during the 2007 and 2008 pollen season</time_frame>
    <description>Asthma/Rhinoconjunctivitis rescue medication score is a component of symptom load. Patients were advised that between visits they could take short acting β-2 agonist rescue medication as initial rescue medication for symptoms of intercurrent bronchospasm. Patients were advised that between visits they could take rescue medication (systemic antihistamines) on an as-needed basis for symptoms of grass pollen allergic rhinoconjunctivitis. The symptom load and all its components were based on the patient's entries in their diaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants by Global Evaluation of Treatment Effectiveness (GETE) Assessment Category Performed by the Investigator</measure>
    <time_frame>52 Weeks (2007) and 104 Weeks (2008) after completion of core study</time_frame>
    <description>The investigator's assessment of the global evaluation of treatment effectiveness (GETE) using a five point scale, which evaluates change in asthma control/symptoms. GETE is scored as 1='excellent', 2='good', 3='moderate', 4='poor', 5='worsening' and (.)='missing').</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants by Global Evaluation of Treatment Effectiveness (GETE) Assessment Category Performed by the Patient</measure>
    <time_frame>52 Weeks (2007) and 104 Weeks (2008) after completion of core study</time_frame>
    <description>The patient's assessment of the global evaluation of treatment effectiveness (GETE) using a five point scale, which evaluates change in asthma control/symptoms. GETE is scored as 1='excellent', 2='good', 3='moderate', 4='poor', 5='worsening' and (.)='missing').</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Questionnaire (ACQ)</measure>
    <time_frame>52 Weeks (2007) and 104 Weeks (2008) after completion of core study</time_frame>
    <description>The Asthma Control Questionnaire (ACQ) was developed and validated for assessing asthma symptom control in patients in clinical trials as well as for individuals in clinical practice. It is a simple questionnaire consisting of seven questions assessing symptoms, airway caliber and rescue β2-agonist use. It uses a 7-point scale. The possible minimum value is 1, the possible maximum value is 7. Higher values represent worse asthma control and quality of life, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Quality of Life Questionnaire (AQLQ)</measure>
    <time_frame>52 Weeks (2007) and 104 Weeks (2008) after completion of core study</time_frame>
    <description>The Asthma Quality of Life Questionnaire (AQLQ) is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma. It consists of 4 domains (symptoms, emotions, exposure to environmental stimuli and activity limitation). Patients are asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale. The overall AQLQ score is the mean response to all 32 questions (low=1, high=7). Higher values represent better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)</measure>
    <time_frame>52 Weeks (2007) and 104 Weeks (2008) after completion of core study</time_frame>
    <description>The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) is a 28-item disease specific questionnaire designed to measure functional impairments that are most important to patients with rhinoconjunctivitis. It consists of 7 domains (activities, sleep, common complaints, practical problems, nasal symptoms, ocular symptoms, and emotions). Patients recall their experiences during the previous week and to score each item on a 7-point scale. The overall RQLQ score is the mean response to all 28 questions (low=1, high=7). Higher values represent worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Quality of Life Questionnaire (AQLQ) and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) - Clinical Differences to Baseline</measure>
    <time_frame>Baseline of core study and 52 Weeks (2007) and 104 Weeks (2008) after completion of core study</time_frame>
    <description>Both the AQLQ and RQLQ clinical differences were categorized as important, moderate, or meaningful improvement; no clinical change; meaningful, moderate, or important impairment. Clinically important differences in scores between any two assessments have been determined by the authors of the AQLQ and RQLQ. Changes in scores of 0.5 to 1.0 are considered clinically meaningful; 1.0 to 1.5 as moderate and &gt; 1.5 as marked clinically important differences for any individual domain or for the overall summary score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment</measure>
    <time_frame>52 Weeks (2007) and 104 Weeks (2008) after completion of core study</time_frame>
    <description>The Work Productivity and Activity Impairment questionnaire measures time missed from work, impairment of work and regular activities. It consists of 6 items. The outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. The minimum value is 0 (0 %), the maximum value is 1 (100%). The recall time is 1 week. For this study WPAI-AA was used defining the specific health problem as allergic asthma, which has been validated by the instrument owner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function as Assessed by Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Assist during 2007 and 2008 pollen season</time_frame>
    <description>The spirometric parameter Forced Expiratory Volume in One Second (FEV1) was measured during grass pollen season before each injection of Depigoid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function as Assessed by Peak Expiratory Flow (PEF)</measure>
    <time_frame>Assist during 2007 and 2008 pollen season</time_frame>
    <description>The spirometric parameter Peak Expiratory Flow (PEF) was measured during grass pollen season before each injection of Depigoid. PEF was collected in the patient diary at seven days after visit 22, 23 and 24 as well as 35, 36 and 37. For analyzing purposes these data were averaged after the respective visits. Missing PEF-values from the patient diary were not replaced.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Allergic Asthma</condition>
  <arm_group>
    <arm_group_label>Depigold+Omalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xolair® (Omalizumab, double-blind core study period only), Depigoid® (grass/rye pollen 50/50)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Depigoid+Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depigoid® (grass/rye pollen 50/50) + Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depigoid</intervention_name>
    <description>Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)</description>
    <arm_group_label>Depigold+Omalizumab</arm_group_label>
    <arm_group_label>Depigoid+Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>anti-IgE (Omalizumab) given during the 2006 core study</description>
    <arm_group_label>Depigold+Omalizumab</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo given during the 2006 core study</description>
    <arm_group_label>Depigoid+Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females of any race who are 12-45 years of age with a body weight ≥ 20 kg and
             ≤ 150 kg and with a total serum IgE level ≥ 30 to ≤ 700 IU/ml (suitable weight for
             dosing)

          -  Patients with the diagnosis of not adequately controlled seasonal grass pollen (and/or
             rye pollen) and allergic asthma with concomitant seasonal allergic rhinoconjunctivitis
             within &gt; 2 previous seasons

          -  patients with a positive RAST (&gt;CAP2) result for grass pollen (and/or rye pollen)
             specific IgE at screening (Visit 1 (V1) or within the previous 12 months.

          -  Patients with FEV1 &gt; 80% of the predicted normal value for the patient at screening
             [V1](demostrable at least 6 hours after last short acting B-2 agonist use or 12 hours
             after last long B-2 acting agonist use).

        Exclusion Criteria:

          -  Females of childbearing potential: pregnancy, birth control,breast-feeding

          -  Concurrent diseases/conditions and history of other diseases/conditions

               1. patients who have a positive history of significant clinical manifestations of
                  allergy as a result of sensitization against tree pollen allergens, weed
                  allergens and perennial allergens (e.g. Aspergillus spores, animal dander, house
                  dust mite).

               2. patients with a history of food or drug related severe anaphylactoid or
                  anaphylactic reaction(s).

          -  Ingredient hypersensitivity

               1. patients with known hypersensitivity to any ingredients, including excipients
                  (sucrose, histidine, polysorbate 20) of the study medication, any immunotherapy,
                  or drugs related to Omalizumab (e.g., monoclonal antibodies, polyclonal gamma
                  globulin).

               2. patients with hypersensitivity to the trail's asthma rescue- or
                  escalation-medication or related drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals, Basel +41 61 324 1111.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigator site</name>
      <address>
        <city>Nuremberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2006</study_first_submitted>
  <study_first_submitted_qc>November 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2006</study_first_posted>
  <results_first_submitted>November 22, 2010</results_first_submitted>
  <results_first_submitted_qc>May 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2011</results_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Depigoid + Omalizumab</title>
          <description>Depigoid administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Omalizumab was given during the 2006 core study.</description>
        </group>
        <group group_id="P2">
          <title>Depigoid + Placebo</title>
          <description>Depigoid dministered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Placebo was given during the 2006 core study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 - 2007</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Between Period 1 and Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 - 2008</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Depigoid + Omalizumab</title>
          <description>Depigoid administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Omalizumab was given during the 2006 core study.</description>
        </group>
        <group group_id="B2">
          <title>Depigoid + Placebo</title>
          <description>Depigoid dministered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Placebo was given during the 2006 core study</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>2007</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.8" spread="9.9"/>
                    <measurement group_id="B2" value="30.4" spread="10.6"/>
                    <measurement group_id="B3" value="29.1" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 (N = 59/55/114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="9.9"/>
                    <measurement group_id="B2" value="30.1" spread="10.9"/>
                    <measurement group_id="B3" value="28.8" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>2007 Open Label (OL) extension phase</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>2008 Open Label (OL) extension phase(N count for Depigoid+Omalizumab is 59 and for Depigoid+Placebo is 55)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;= 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participated in 2007 but not in 2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <description>2007 Open Label (OL) extension phase</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2007 Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007 Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <description>2008 Open Label (OL) extension phase(N count for Depigoid+Omalizumab is 59 and for Depigoid+Placebo is 55)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2008 Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participated in 2007 but not in 2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>2008 Open Label (OL) extension phase (N count for Depigoid+Omalizumab is 59 and for Depigoid+Placebo is 55)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participated in 2007 but not in 2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>2007 Open Label (OL) extension phase</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Daily Symptom Load</title>
        <description>The daily symptom load (low=0, high=unbounded) represents the daily combined asthma and rhinoconjunctivitis symptom severity scores plus the daily asthma rescue medication score based on patient diary entries. A higher score indicates a worse patient asthma condition. Symptoms (e.g. - difficulty breathing, cough, tightness of chest, sneezing, itchy nose, red eyes, etc.) were evaluated daily by the patient using a 4-point scale (0=no symptom, 1=mild, 2=moderate, 3=severe). Point values were assigned by specific rescue medication usage. The daily scores were averaged over pollen days by site.</description>
        <time_frame>Recorded daily during the 2007 and 2008 pollen season</time_frame>
        <population>Intent-to-Treat (ITT). The complete analysis population who consisted of all patients that received at least one dose of study drug was used for all efficacy and safety evaluations in this extension period.</population>
        <group_list>
          <group group_id="O1">
            <title>Depigoid + Omalizumab</title>
            <description>Depigoid administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Omalizumab was given during the 2006 core study.</description>
          </group>
          <group group_id="O2">
            <title>Depigoid + Placebo</title>
            <description>Depigoid dministered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Placebo was given during the 2006 core study</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Symptom Load</title>
          <description>The daily symptom load (low=0, high=unbounded) represents the daily combined asthma and rhinoconjunctivitis symptom severity scores plus the daily asthma rescue medication score based on patient diary entries. A higher score indicates a worse patient asthma condition. Symptoms (e.g. - difficulty breathing, cough, tightness of chest, sneezing, itchy nose, red eyes, etc.) were evaluated daily by the patient using a 4-point scale (0=no symptom, 1=mild, 2=moderate, 3=severe). Point values were assigned by specific rescue medication usage. The daily scores were averaged over pollen days by site.</description>
          <population>Intent-to-Treat (ITT). The complete analysis population who consisted of all patients that received at least one dose of study drug was used for all efficacy and safety evaluations in this extension period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2007</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.99"/>
                    <measurement group_id="O2" value="1.10" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="1.74"/>
                    <measurement group_id="O2" value="0.97" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma/Rhinoconjunctivitis Symptom Severity Score</title>
        <description>The symptom severity score was defined as the mean of the daily symptom severity scores (asthma symptoms during the day, asthma symptoms at night, rhinitis symptoms, and conjunctivitis symptoms) during the pollen season. The daily symptom severity scores were evaluated daily by the patient using a 4-point scale (0 = none (no symptom), 1 = mild, 2 = moderate, 3 = severe) and were recorded in a patient diary. The possible minimum value for the Asthma/Rhinoconjunctivitis Symptom Severity Score is 0, and the possible maximum value is 3. Higher values represent a worse outcome.</description>
        <time_frame>Recorded daily during the 2007 and 2008 pollen season</time_frame>
        <population>Intent-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Depigoid + Omalizumab</title>
            <description>Depigoid administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Omalizumab was given during the 2006 core study.</description>
          </group>
          <group group_id="O2">
            <title>Depigoid + Placebo</title>
            <description>Depigoid dministered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Placebo was given during the 2006 core study</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma/Rhinoconjunctivitis Symptom Severity Score</title>
          <description>The symptom severity score was defined as the mean of the daily symptom severity scores (asthma symptoms during the day, asthma symptoms at night, rhinitis symptoms, and conjunctivitis symptoms) during the pollen season. The daily symptom severity scores were evaluated daily by the patient using a 4-point scale (0 = none (no symptom), 1 = mild, 2 = moderate, 3 = severe) and were recorded in a patient diary. The possible minimum value for the Asthma/Rhinoconjunctivitis Symptom Severity Score is 0, and the possible maximum value is 3. Higher values represent a worse outcome.</description>
          <population>Intent-to-Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2007</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.40"/>
                    <measurement group_id="O2" value="0.55" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.42"/>
                    <measurement group_id="O2" value="0.50" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma/Rhinoconjunctivitis Rescue Medication Score</title>
        <description>Asthma/Rhinoconjunctivitis rescue medication score is a component of symptom load. Patients were advised that between visits they could take short acting β-2 agonist rescue medication as initial rescue medication for symptoms of intercurrent bronchospasm. Patients were advised that between visits they could take rescue medication (systemic antihistamines) on an as-needed basis for symptoms of grass pollen allergic rhinoconjunctivitis. The symptom load and all its components were based on the patient’s entries in their diaries.</description>
        <time_frame>Recorded daily during the 2007 and 2008 pollen season</time_frame>
        <population>Intent-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Depigoid + Omalizumab</title>
            <description>Depigoid administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Omalizumab was given during the 2006 core study.</description>
          </group>
          <group group_id="O2">
            <title>Depigoid + Placebo</title>
            <description>Depigoid dministered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Placebo was given during the 2006 core study</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma/Rhinoconjunctivitis Rescue Medication Score</title>
          <description>Asthma/Rhinoconjunctivitis rescue medication score is a component of symptom load. Patients were advised that between visits they could take short acting β-2 agonist rescue medication as initial rescue medication for symptoms of intercurrent bronchospasm. Patients were advised that between visits they could take rescue medication (systemic antihistamines) on an as-needed basis for symptoms of grass pollen allergic rhinoconjunctivitis. The symptom load and all its components were based on the patient’s entries in their diaries.</description>
          <population>Intent-to-Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2007</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.80"/>
                    <measurement group_id="O2" value="0.55" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="1.60"/>
                    <measurement group_id="O2" value="0.47" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants by Global Evaluation of Treatment Effectiveness (GETE) Assessment Category Performed by the Investigator</title>
        <description>The investigator's assessment of the global evaluation of treatment effectiveness (GETE) using a five point scale, which evaluates change in asthma control/symptoms. GETE is scored as 1=’excellent’, 2=’good’, 3=’moderate’, 4=’poor’, 5=’worsening’ and (.)=’missing’).</description>
        <time_frame>52 Weeks (2007) and 104 Weeks (2008) after completion of core study</time_frame>
        <population>Intent-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Depigoid + Omalizumab</title>
            <description>Depigoid administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Omalizumab was given during the 2006 core study.</description>
          </group>
          <group group_id="O2">
            <title>Depigoid + Placebo</title>
            <description>Depigoid dministered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Placebo was given during the 2006 core study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants by Global Evaluation of Treatment Effectiveness (GETE) Assessment Category Performed by the Investigator</title>
          <description>The investigator's assessment of the global evaluation of treatment effectiveness (GETE) using a five point scale, which evaluates change in asthma control/symptoms. GETE is scored as 1=’excellent’, 2=’good’, 3=’moderate’, 4=’poor’, 5=’worsening’ and (.)=’missing’).</description>
          <population>Intent-to-Treat (ITT)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2007: 1 = Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00"/>
                    <measurement group_id="O2" value="9.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007:2 = Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.00"/>
                    <measurement group_id="O2" value="54.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007:3 = Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67"/>
                    <measurement group_id="O2" value="21.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007:4 = Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67"/>
                    <measurement group_id="O2" value="14.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007:5 = Worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007:(.) = Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007:Responders (1+2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="63.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008: 1 = Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.64"/>
                    <measurement group_id="O2" value="14.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008:2 = Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.15"/>
                    <measurement group_id="O2" value="30.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008:3 = Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.64"/>
                    <measurement group_id="O2" value="43.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008:4 = Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78"/>
                    <measurement group_id="O2" value="9.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008:5 = Worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008:(.) = Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78"/>
                    <measurement group_id="O2" value="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008:Responders (1+2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.79"/>
                    <measurement group_id="O2" value="45.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants by Global Evaluation of Treatment Effectiveness (GETE) Assessment Category Performed by the Patient</title>
        <description>The patient's assessment of the global evaluation of treatment effectiveness (GETE) using a five point scale, which evaluates change in asthma control/symptoms. GETE is scored as 1=’excellent’, 2=’good’, 3=’moderate’, 4=’poor’, 5=’worsening’ and (.)=’missing’).</description>
        <time_frame>52 Weeks (2007) and 104 Weeks (2008) after completion of core study</time_frame>
        <population>Intent-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Depigoid + Omalizumab</title>
            <description>Depigoid administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Omalizumab was given during the 2006 core study.</description>
          </group>
          <group group_id="O2">
            <title>Depigoid + Placebo</title>
            <description>Depigoid dministered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Placebo was given during the 2006 core study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants by Global Evaluation of Treatment Effectiveness (GETE) Assessment Category Performed by the Patient</title>
          <description>The patient's assessment of the global evaluation of treatment effectiveness (GETE) using a five point scale, which evaluates change in asthma control/symptoms. GETE is scored as 1=’excellent’, 2=’good’, 3=’moderate’, 4=’poor’, 5=’worsening’ and (.)=’missing’).</description>
          <population>Intent-to-Treat (ITT)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2007: 1 = Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.33"/>
                    <measurement group_id="O2" value="7.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007: 2 = Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.00"/>
                    <measurement group_id="O2" value="50.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007: 3 = Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.33"/>
                    <measurement group_id="O2" value="18.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007: 4 = Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00"/>
                    <measurement group_id="O2" value="21.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007: 5 = Worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007: (.) = Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67"/>
                    <measurement group_id="O2" value="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008: 1 = Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.56"/>
                    <measurement group_id="O2" value="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008: 2 = Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.76"/>
                    <measurement group_id="O2" value="43.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008: 3 = Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.42"/>
                    <measurement group_id="O2" value="36.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008: 4 = Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78"/>
                    <measurement group_id="O2" value="9.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008: 5 = Worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69"/>
                    <measurement group_id="O2" value="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008: (.) = Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78"/>
                    <measurement group_id="O2" value="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Control Questionnaire (ACQ)</title>
        <description>The Asthma Control Questionnaire (ACQ) was developed and validated for assessing asthma symptom control in patients in clinical trials as well as for individuals in clinical practice. It is a simple questionnaire consisting of seven questions assessing symptoms, airway caliber and rescue β2-agonist use. It uses a 7-point scale. The possible minimum value is 1, the possible maximum value is 7. Higher values represent worse asthma control and quality of life, respectively.</description>
        <time_frame>52 Weeks (2007) and 104 Weeks (2008) after completion of core study</time_frame>
        <population>Intent-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Depigoid + Omalizumab</title>
            <description>Depigoid administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Omalizumab was given during the 2006 core study.</description>
          </group>
          <group group_id="O2">
            <title>Depigoid + Placebo</title>
            <description>Depigoid dministered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Placebo was given during the 2006 core study</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Control Questionnaire (ACQ)</title>
          <description>The Asthma Control Questionnaire (ACQ) was developed and validated for assessing asthma symptom control in patients in clinical trials as well as for individuals in clinical practice. It is a simple questionnaire consisting of seven questions assessing symptoms, airway caliber and rescue β2-agonist use. It uses a 7-point scale. The possible minimum value is 1, the possible maximum value is 7. Higher values represent worse asthma control and quality of life, respectively.</description>
          <population>Intent-to-Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2007</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.68"/>
                    <measurement group_id="O2" value="1.97" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="0.71"/>
                    <measurement group_id="O2" value="1.95" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Quality of Life Questionnaire (AQLQ)</title>
        <description>The Asthma Quality of Life Questionnaire (AQLQ) is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma. It consists of 4 domains (symptoms, emotions, exposure to environmental stimuli and activity limitation). Patients are asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale. The overall AQLQ score is the mean response to all 32 questions (low=1, high=7). Higher values represent better quality of life.</description>
        <time_frame>52 Weeks (2007) and 104 Weeks (2008) after completion of core study</time_frame>
        <population>Intent-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Depigoid + Omalizumab</title>
            <description>Depigoid administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Omalizumab was given during the 2006 core study.</description>
          </group>
          <group group_id="O2">
            <title>Depigoid + Placebo</title>
            <description>Depigoid dministered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Placebo was given during the 2006 core study</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Quality of Life Questionnaire (AQLQ)</title>
          <description>The Asthma Quality of Life Questionnaire (AQLQ) is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma. It consists of 4 domains (symptoms, emotions, exposure to environmental stimuli and activity limitation). Patients are asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale. The overall AQLQ score is the mean response to all 32 questions (low=1, high=7). Higher values represent better quality of life.</description>
          <population>Intent-to-Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2007</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.19" spread="0.81"/>
                    <measurement group_id="O2" value="6.06" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.22" spread="0.77"/>
                    <measurement group_id="O2" value="6.21" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)</title>
        <description>The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) is a 28-item disease specific questionnaire designed to measure functional impairments that are most important to patients with rhinoconjunctivitis. It consists of 7 domains (activities, sleep, common complaints, practical problems, nasal symptoms, ocular symptoms, and emotions). Patients recall their experiences during the previous week and to score each item on a 7-point scale. The overall RQLQ score is the mean response to all 28 questions (low=1, high=7). Higher values represent worse quality of life.</description>
        <time_frame>52 Weeks (2007) and 104 Weeks (2008) after completion of core study</time_frame>
        <population>Intent-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Depigoid + Omalizumab</title>
            <description>Depigoid administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Omalizumab was given during the 2006 core study.</description>
          </group>
          <group group_id="O2">
            <title>Depigoid + Placebo</title>
            <description>Depigoid dministered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Placebo was given during the 2006 core study</description>
          </group>
        </group_list>
        <measure>
          <title>Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)</title>
          <description>The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) is a 28-item disease specific questionnaire designed to measure functional impairments that are most important to patients with rhinoconjunctivitis. It consists of 7 domains (activities, sleep, common complaints, practical problems, nasal symptoms, ocular symptoms, and emotions). Patients recall their experiences during the previous week and to score each item on a 7-point scale. The overall RQLQ score is the mean response to all 28 questions (low=1, high=7). Higher values represent worse quality of life.</description>
          <population>Intent-to-Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2007</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="0.86"/>
                    <measurement group_id="O2" value="2.08" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="0.99"/>
                    <measurement group_id="O2" value="1.98" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Quality of Life Questionnaire (AQLQ) and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) - Clinical Differences to Baseline</title>
        <description>Both the AQLQ and RQLQ clinical differences were categorized as important, moderate, or meaningful improvement; no clinical change; meaningful, moderate, or important impairment. Clinically important differences in scores between any two assessments have been determined by the authors of the AQLQ and RQLQ. Changes in scores of 0.5 to 1.0 are considered clinically meaningful; 1.0 to 1.5 as moderate and &gt; 1.5 as marked clinically important differences for any individual domain or for the overall summary score.</description>
        <time_frame>Baseline of core study and 52 Weeks (2007) and 104 Weeks (2008) after completion of core study</time_frame>
        <population>Intent-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Depigoid + Omalizumab</title>
            <description>Depigoid administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Omalizumab was given during the 2006 core study.</description>
          </group>
          <group group_id="O2">
            <title>Depigoid + Placebo</title>
            <description>Depigoid dministered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Placebo was given during the 2006 core study</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Quality of Life Questionnaire (AQLQ) and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) - Clinical Differences to Baseline</title>
          <description>Both the AQLQ and RQLQ clinical differences were categorized as important, moderate, or meaningful improvement; no clinical change; meaningful, moderate, or important impairment. Clinically important differences in scores between any two assessments have been determined by the authors of the AQLQ and RQLQ. Changes in scores of 0.5 to 1.0 are considered clinically meaningful; 1.0 to 1.5 as moderate and &gt; 1.5 as marked clinically important differences for any individual domain or for the overall summary score.</description>
          <population>Intent-to-Treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2007 AQLQ: important improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007 AQLQ: moderate improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007 AQLQ: meaningful improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007 AQLQ: no clinical change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007 AQLQ: meaningful impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007 AQLQ: moderate impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007 AQLQ: important impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007 AQLQ: missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007 RQLQ: important improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007 RQLQ: moderate improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007 RQLQ: meaningful improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007 RQLQ: no clinical change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007 RQLQ: meaningful impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007 RQLQ: moderate impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007 RQLQ: important impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007 RQLQ: missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 AQLQ: important improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 AQLQ: moderate improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 AQLQ: meaningful improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 AQLQ: no clinical change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 AQLQ: meaningful impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 AQLQ: moderate impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 AQLQ: important impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 AQLQ: missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 RQLQ: important improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 RQLQ: moderate improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 RQLQ: meaningful improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 RQLQ: no clinical change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 RQLQ: meaningful impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 RQLQ: moderate impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 RQLQ: important impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008 RQLQ: missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Productivity and Activity Impairment</title>
        <description>The Work Productivity and Activity Impairment questionnaire measures time missed from work, impairment of work and regular activities. It consists of 6 items. The outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. The minimum value is 0 (0 %), the maximum value is 1 (100%). The recall time is 1 week. For this study WPAI-AA was used defining the specific health problem as allergic asthma, which has been validated by the instrument owner.</description>
        <time_frame>52 Weeks (2007) and 104 Weeks (2008) after completion of core study</time_frame>
        <population>Intent-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Depigoid + Omalizumab</title>
            <description>Depigoid administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Omalizumab was given during the 2006 core study.</description>
          </group>
          <group group_id="O2">
            <title>Depigoid + Placebo</title>
            <description>Depigoid dministered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Placebo was given during the 2006 core study</description>
          </group>
        </group_list>
        <measure>
          <title>Work Productivity and Activity Impairment</title>
          <description>The Work Productivity and Activity Impairment questionnaire measures time missed from work, impairment of work and regular activities. It consists of 6 items. The outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. The minimum value is 0 (0 %), the maximum value is 1 (100%). The recall time is 1 week. For this study WPAI-AA was used defining the specific health problem as allergic asthma, which has been validated by the instrument owner.</description>
          <population>Intent-to-Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2007: Work time missed due to asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.01"/>
                    <measurement group_id="O2" value="0.01" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007: Impairment while working due to asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.20"/>
                    <measurement group_id="O2" value="0.09" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007: Overall work impairment due to asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.20"/>
                    <measurement group_id="O2" value="0.10" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007: Activitiy impairment due to asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.15"/>
                    <measurement group_id="O2" value="0.17" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007Time in school activities missed due to asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.01" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007:Impairment in school activities due to asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.09"/>
                    <measurement group_id="O2" value="0.11" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2007: Overall impairment/activities due to asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.01" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008: Work time missed due to asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.01"/>
                    <measurement group_id="O2" value="0.04" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008: Impairment while working due to asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.13"/>
                    <measurement group_id="O2" value="0.10" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008: Overall work impairment due to asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.14"/>
                    <measurement group_id="O2" value="0.10" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008: Activitiy impairment due to asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.18"/>
                    <measurement group_id="O2" value="0.15" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008Time in school activities missed due to asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008:Impairment in school activities due to asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.06"/>
                    <measurement group_id="O2" value="0.14" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008: Overall impairment/activities due to asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function as Assessed by Forced Expiratory Volume in One Second (FEV1)</title>
        <description>The spirometric parameter Forced Expiratory Volume in One Second (FEV1) was measured during grass pollen season before each injection of Depigoid.</description>
        <time_frame>Assist during 2007 and 2008 pollen season</time_frame>
        <population>Intent-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Depigoid + Omalizumab</title>
            <description>Depigoid administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Omalizumab was given during the 2006 core study.</description>
          </group>
          <group group_id="O2">
            <title>Depigoid + Placebo</title>
            <description>Depigoid dministered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Placebo was given during the 2006 core study</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function as Assessed by Forced Expiratory Volume in One Second (FEV1)</title>
          <description>The spirometric parameter Forced Expiratory Volume in One Second (FEV1) was measured during grass pollen season before each injection of Depigoid.</description>
          <population>Intent-to-Treat (ITT)</population>
          <units>milliliters (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2007: FEV1 (best test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3886" spread="740"/>
                    <measurement group_id="O2" value="3661" spread="720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008: FEV1 (best test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3814" spread="721"/>
                    <measurement group_id="O2" value="3574" spread="691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function as Assessed by Peak Expiratory Flow (PEF)</title>
        <description>The spirometric parameter Peak Expiratory Flow (PEF) was measured during grass pollen season before each injection of Depigoid. PEF was collected in the patient diary at seven days after visit 22, 23 and 24 as well as 35, 36 and 37. For analyzing purposes these data were averaged after the respective visits. Missing PEF-values from the patient diary were not replaced.</description>
        <time_frame>Assist during 2007 and 2008 pollen season</time_frame>
        <population>Intent-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Depigoid + Omalizumab</title>
            <description>Depigoid administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Omalizumab was given during the 2006 core study.</description>
          </group>
          <group group_id="O2">
            <title>Depigoid + Placebo</title>
            <description>Depigoid dministered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Placebo was given during the 2006 core study</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function as Assessed by Peak Expiratory Flow (PEF)</title>
          <description>The spirometric parameter Peak Expiratory Flow (PEF) was measured during grass pollen season before each injection of Depigoid. PEF was collected in the patient diary at seven days after visit 22, 23 and 24 as well as 35, 36 and 37. For analyzing purposes these data were averaged after the respective visits. Missing PEF-values from the patient diary were not replaced.</description>
          <population>Intent-to-Treat (ITT)</population>
          <units>liters per minute (L/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2007: PEF (V23 or 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="465.6" spread="111.5"/>
                    <measurement group_id="O2" value="441.0" spread="111.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2008: PEF (V23 or 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="463.9" spread="113.2"/>
                    <measurement group_id="O2" value="446.1" spread="116.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Depigoid + Omalizumab 2007</title>
          <description>Depigoid administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Omalizumab was given during the 2006 core study.</description>
        </group>
        <group group_id="E2">
          <title>Depigoid + Omalizumab 2008</title>
          <description>Depigoid administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Omalizumab was given during the 2006 core study.</description>
        </group>
        <group group_id="E3">
          <title>Depigoid + Placebo 2007</title>
          <description>Depigoid dministered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Placebo was given during the 2006 core study</description>
        </group>
        <group group_id="E4">
          <title>Depigoid + Placebo 2008</title>
          <description>Depigoid dministered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL). Placebo was given during the 2006 core study</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study Start Date: February 2006 (core study)</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

